Celleuxs launches “broad cell line” disposable bioreactor

By Gareth Macdonald

- Last updated on GMT

Related tags Merck kgaa Biotechnology

Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.

The new reactor, the CellMaker Plus, features oxygen generation capability, dissolved oxygen (DO) and pH sensors that, the UK firm said, can be adjusted to enable the use of the “broadest range of cell types​.”

This contention is further supported by the wide variety of lines used during the system’s development, which range from laboratory standbys like E.coli​ and Pichia​ to “more challenging” insect and mammalian cells.

Compatibility with a large number of cell lines gives Cellexus the biggest possible customer base for the product, which is important given that the disposable reactor market is already highly competitive.

This was highlighted in recent​ months with the launch of yet another new disposable bioreactor by ATMI and the formation of a reactor-focused development​ partnership by processing industry heavyweights Pall and New Brunswick.

And in the last few weeks​ Merck KGaA acquired Millipore which, given that growth in the bio-manufacturing was a key driver for the deal, makes it likely that competition in the bioreactor field will only increase.

Unique aeration tech

The new Cellexus reactor also uses the firm's range of disposable culture bags, designed to minimise cleaning requirements, as well as a unique aeration technology that the firm said is uniquely beneficial for biomanufacturing.

Whereas other disposable systems require shakers, rockers, rollers or large environmental chambers, the CellMaker PLUS employs proprietary airlift technology to mix, aerate and maintain cell suspension​.”

Try before you buy

The CellMaker Plus unit, which is available in eight and 50 liter versions, is like other products in the range available under the UK processing technology firm’s try before you buy rental​ plan.

The scheme, which was launched in September 2007 for Cellexus’ CellMaker Lite2 technology, enables manufacturers to rent the reactors on a monthly basis allowing them to optimise the system for large-scale production.

Related news

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...